



## → OMPs IN THE **EU** AND **SPAIN**




## → JAN-APRIL 2024



## → OMPs **REIMBURSED** IN **SPAIN**

Jan-April 2024\*  
OMPs REIMBURSED BY THERAPEUTIC AREA




**85**  
OMPs are currently reimbursed by the NHS


**48% (41)**  
OMPs restrictedly reimbursed (with restricted indications or unreimbursed indications)

## → % REIMBURSED

OMPs WITH MARKETING AUTHORISATION  
REIMBURSED BY THE NHS 2020 - 2024




OMPs WITH NC REIMBURSED BY THE  
NHS 2020 - 2024




## → AVERAGE WAITING TIME


MONTHS BETWEEN NC AND INCORPORATION INTO THE NHS




## → OMPs **NOT REIMBURSED** IN **SPAIN**




NUMBER OF OMPs NOT REIMBURSED BY YEAR OF NC




NUMBER OF OMPs NOT REIMBURSED BY THERAPEUTIC AREA




## → OMPs WITH MA **PENDING** TO ARRIVE IN **SPAIN**




## → % OMPs WITH MA WITHOUT NC




WAITING TIME SINCE MA




BY THERAPEUTIC AREA



## → **ADVANCED THERAPIES** WITH ORPHAN DESIGNATION



## → ADVANCED THERAPIES WITH MA, NC AND REIMBURSING 2018-2024



Note: for the preparation of this report it has not been possible to take into account drugs that are available in Spain under specific situations and special authorisations within the framework of Royal Decree 1015/2009 (compassionate use, use under conditions other than those authorised or access to foreign medicines), as the data were not available.

\*Aggregated data as of April 30, 2024.

\*\*The 16 Advanced Therapies with OD and MA would be included in the total of 202 MMH with OD and in the 149 MMH with MA, as they are TTAAs with trade name.